A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous Å6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer

Sharad A Ghamande, Michael H. Silverman, Warner Huh, Kian Behbakht, Greg Ball, Luceli Cuasay, Sidse O. Würtz, Nils Brunner, Michael A. Gold

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Objectives: Å6 is a novel peptide that interferes with single-chain urokinase plasminogen activator activity and has shown anti-angiogenic, anti-migratory, and anti-invasive properties. We evaluated clinical efficacy and safety of subcutaneously administered Å6 in women with epithelial ovarian cancer. Methods: Women with epithelial ovarian, fallopian tube, or primary peritoneal cancer in clinical remission after first-line chemotherapy with 2 consecutive increases of CA125 values above normal but with no disease on physical examination or imaging studies were randomly assigned to receive daily subcutaneous injections of placebo, low-dose Å6 (150 mg), or high-dose Å6 (300 mg) until disease progression or end of study participation. Primary endpoints were time to clinical progression of disease and safety of Å6. Secondary endpoints were changes in serum CA125 and biomarkers of the urokinase system. Results: Data are available for 24 women (placebo, n = 12; low-dose, n = 8; high-dose n = 4). Å6 therapy was associated with a statistically significant delay in time to clinical progression (log-rank p-value 0.01) with a median of 100 days (95% CI: 64,168) for women who received Å6 compared with 49 days (95% CI: 29,67) for women who received placebo. The treatments appeared to be well tolerated. Treatment was not associated with CA125 response (p = 0.44). On-treatment values for plasma urokinase plasminogen activator receptor were statistically significantly lower in the Å6 groups compared with placebo (p = 0.02). Conclusions: Å6 therapy increases time to clinical disease progression and appears to be well tolerated in this patient population.

Original languageEnglish (US)
Pages (from-to)89-94
Number of pages6
JournalGynecologic Oncology
Volume111
Issue number1
DOIs
StatePublished - Oct 1 2008

Fingerprint

Controlled Clinical Trials
Placebos
Safety
Drug Therapy
Disease Progression
Urokinase-Type Plasminogen Activator
Urokinase Plasminogen Activator Receptors
Therapeutics
Fallopian Tubes
Plasminogen Activators
Subcutaneous Injections
Physical Examination
Reference Values
Biomarkers
Ovarian epithelial cancer
Peptides
Serum
Population
Neoplasms

Keywords

  • A6 therapy
  • Asymptomatic CA 125 progression
  • Epithelial

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous Å6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer. / Ghamande, Sharad A; Silverman, Michael H.; Huh, Warner; Behbakht, Kian; Ball, Greg; Cuasay, Luceli; Würtz, Sidse O.; Brunner, Nils; Gold, Michael A.

In: Gynecologic Oncology, Vol. 111, No. 1, 01.10.2008, p. 89-94.

Research output: Contribution to journalArticle

Ghamande, Sharad A ; Silverman, Michael H. ; Huh, Warner ; Behbakht, Kian ; Ball, Greg ; Cuasay, Luceli ; Würtz, Sidse O. ; Brunner, Nils ; Gold, Michael A. / A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous Å6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer. In: Gynecologic Oncology. 2008 ; Vol. 111, No. 1. pp. 89-94.
@article{8d42fe41075c4d569e128df2505beca4,
title = "A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous {\AA}6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer",
abstract = "Objectives: {\AA}6 is a novel peptide that interferes with single-chain urokinase plasminogen activator activity and has shown anti-angiogenic, anti-migratory, and anti-invasive properties. We evaluated clinical efficacy and safety of subcutaneously administered {\AA}6 in women with epithelial ovarian cancer. Methods: Women with epithelial ovarian, fallopian tube, or primary peritoneal cancer in clinical remission after first-line chemotherapy with 2 consecutive increases of CA125 values above normal but with no disease on physical examination or imaging studies were randomly assigned to receive daily subcutaneous injections of placebo, low-dose {\AA}6 (150 mg), or high-dose {\AA}6 (300 mg) until disease progression or end of study participation. Primary endpoints were time to clinical progression of disease and safety of {\AA}6. Secondary endpoints were changes in serum CA125 and biomarkers of the urokinase system. Results: Data are available for 24 women (placebo, n = 12; low-dose, n = 8; high-dose n = 4). {\AA}6 therapy was associated with a statistically significant delay in time to clinical progression (log-rank p-value 0.01) with a median of 100 days (95{\%} CI: 64,168) for women who received {\AA}6 compared with 49 days (95{\%} CI: 29,67) for women who received placebo. The treatments appeared to be well tolerated. Treatment was not associated with CA125 response (p = 0.44). On-treatment values for plasma urokinase plasminogen activator receptor were statistically significantly lower in the {\AA}6 groups compared with placebo (p = 0.02). Conclusions: {\AA}6 therapy increases time to clinical disease progression and appears to be well tolerated in this patient population.",
keywords = "A6 therapy, Asymptomatic CA 125 progression, Epithelial",
author = "Ghamande, {Sharad A} and Silverman, {Michael H.} and Warner Huh and Kian Behbakht and Greg Ball and Luceli Cuasay and W{\"u}rtz, {Sidse O.} and Nils Brunner and Gold, {Michael A.}",
year = "2008",
month = "10",
day = "1",
doi = "10.1016/j.ygyno.2008.06.028",
language = "English (US)",
volume = "111",
pages = "89--94",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous Å6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer

AU - Ghamande, Sharad A

AU - Silverman, Michael H.

AU - Huh, Warner

AU - Behbakht, Kian

AU - Ball, Greg

AU - Cuasay, Luceli

AU - Würtz, Sidse O.

AU - Brunner, Nils

AU - Gold, Michael A.

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Objectives: Å6 is a novel peptide that interferes with single-chain urokinase plasminogen activator activity and has shown anti-angiogenic, anti-migratory, and anti-invasive properties. We evaluated clinical efficacy and safety of subcutaneously administered Å6 in women with epithelial ovarian cancer. Methods: Women with epithelial ovarian, fallopian tube, or primary peritoneal cancer in clinical remission after first-line chemotherapy with 2 consecutive increases of CA125 values above normal but with no disease on physical examination or imaging studies were randomly assigned to receive daily subcutaneous injections of placebo, low-dose Å6 (150 mg), or high-dose Å6 (300 mg) until disease progression or end of study participation. Primary endpoints were time to clinical progression of disease and safety of Å6. Secondary endpoints were changes in serum CA125 and biomarkers of the urokinase system. Results: Data are available for 24 women (placebo, n = 12; low-dose, n = 8; high-dose n = 4). Å6 therapy was associated with a statistically significant delay in time to clinical progression (log-rank p-value 0.01) with a median of 100 days (95% CI: 64,168) for women who received Å6 compared with 49 days (95% CI: 29,67) for women who received placebo. The treatments appeared to be well tolerated. Treatment was not associated with CA125 response (p = 0.44). On-treatment values for plasma urokinase plasminogen activator receptor were statistically significantly lower in the Å6 groups compared with placebo (p = 0.02). Conclusions: Å6 therapy increases time to clinical disease progression and appears to be well tolerated in this patient population.

AB - Objectives: Å6 is a novel peptide that interferes with single-chain urokinase plasminogen activator activity and has shown anti-angiogenic, anti-migratory, and anti-invasive properties. We evaluated clinical efficacy and safety of subcutaneously administered Å6 in women with epithelial ovarian cancer. Methods: Women with epithelial ovarian, fallopian tube, or primary peritoneal cancer in clinical remission after first-line chemotherapy with 2 consecutive increases of CA125 values above normal but with no disease on physical examination or imaging studies were randomly assigned to receive daily subcutaneous injections of placebo, low-dose Å6 (150 mg), or high-dose Å6 (300 mg) until disease progression or end of study participation. Primary endpoints were time to clinical progression of disease and safety of Å6. Secondary endpoints were changes in serum CA125 and biomarkers of the urokinase system. Results: Data are available for 24 women (placebo, n = 12; low-dose, n = 8; high-dose n = 4). Å6 therapy was associated with a statistically significant delay in time to clinical progression (log-rank p-value 0.01) with a median of 100 days (95% CI: 64,168) for women who received Å6 compared with 49 days (95% CI: 29,67) for women who received placebo. The treatments appeared to be well tolerated. Treatment was not associated with CA125 response (p = 0.44). On-treatment values for plasma urokinase plasminogen activator receptor were statistically significantly lower in the Å6 groups compared with placebo (p = 0.02). Conclusions: Å6 therapy increases time to clinical disease progression and appears to be well tolerated in this patient population.

KW - A6 therapy

KW - Asymptomatic CA 125 progression

KW - Epithelial

UR - http://www.scopus.com/inward/record.url?scp=52049127235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52049127235&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2008.06.028

DO - 10.1016/j.ygyno.2008.06.028

M3 - Article

C2 - 18760451

AN - SCOPUS:52049127235

VL - 111

SP - 89

EP - 94

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -